SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in two upcoming investor conferences in October 2024. Details are as follows:
-
2024 RBC Capital Markets Biotechnology Private Company Virtual Conference
- Actio’s CEO David Goldstein, Ph.D., will participate in a fireside chat on Tuesday, October 1, 2024, at 8:40 a.m. ET, and one-on-one investor meetings
-
Leerink Partners Biopharma Private Company Connect
- Management will participate in one-on-one investor meetings on October 23, 2024
About Actio Biosciences
Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Actio is advancing two lead rare disease programs with first-in-class potential for the treatment of Charcot-Marie-Tooth Disease, Type 2C (CMT2C) and genetic epilepsy. The CMT2C program is expected to enter a Phase 1 clinical trial by year-end 2024, with the genetic epilepsy program entering a Phase 1 clinical trial in 2025. Founded in October 2021, the San Diego-based company is led by leaders in genetics and drug development and backed by top healthcare investors. For more information, please visit ActioBiosciences.com and follow us on LinkedIn.
